Prognostic Impact of the Type of Anaesthesia Used During the Excision of Primary Cutaneous Melanoma
Overview
Affiliations
The prognostic value of the type of anaesthesia used for the excision of malignant tumours has been a subject of controversy. Cell-mediated as well as humoral immune responses can be compromised after general anaesthesia, and recurrences may therefore occur more frequently. On the other hand, excision of primary tumours under local anaesthesia might also influence the prognosis unfavourably. The aim of the present study was to determine the prognostic impact of general and local anaesthesia for the primary excision of cutaneous melanoma. Follow-up data of 4329 patients on the Central Melanoma Registry of the German Dermatological Society were analysed. Cox proportional hazards analysis was performed to evaluate the independent significance of the prognostic factors, and survival probabilities were calculated for matched pairs using Kaplan-Meier estimates. Statistical analysis revealed an independent significant effect on survival for tumour thickness, ulceration, level of invasion, anatomical site and gender. General anaesthesia for primary excision of melanoma was associated with a decrease in the survival rate (relative risk 1.46, P<0.0001). This study revealed a slight but significantly increased risk of death for patients treated with general anaesthesia for the primary excision of melanoma. Therefore local anaesthesia should be preferred for the treatment of primary melanoma.
Li Y, Ma P, Li J, Wu F, Guo M, Zhou E Cell Biosci. 2024; 14(1):100.
PMID: 39090653 PMC: 11295430. DOI: 10.1186/s13578-024-01254-0.
Kim J, Yoon S, Song I, Lee K, Hwang W, Kim H Perioper Med (Lond). 2024; 13(1):79.
PMID: 39039548 PMC: 11264408. DOI: 10.1186/s13741-024-00436-1.
Anesthesia and cancer recurrence: a narrative review.
Ahn H Anesth Pain Med (Seoul). 2024; 19(2):94-108.
PMID: 38725164 PMC: 11089301. DOI: 10.17085/apm.24041.
Impact of anesthesia choice in cutaneous melanoma surgery.
Benesch M, Skitzki J Melanoma Res. 2023; 34(1):16-21.
PMID: 37924527 PMC: 10842619. DOI: 10.1097/CMR.0000000000000936.
Tearle J, Arjunan S, Tay S, Colakoglu F, Cremasco J, Golo M Cancer Res Commun. 2023; 3(8):1524-1537.
PMID: 37575281 PMC: 10416804. DOI: 10.1158/2767-9764.CRC-22-0305.